Biotech

0 242
Cellectar Biosciences Inc CLRB Stock News

Cellectar Biosciences Inc (NASDAQ: CLRB) isn’t having the best of days in the market today. However, if you take a look at the way the stock flew yesterday, you wouldn’t be very concerned. That’s because the company released data with regard to the fact that it has generated numerous PDC molecules that show incredible pharmacologic activity. At the moment (9:29), CLRB is trading at $1.77 per share after a loss of $0.02 per share or 1.26%. However, these declines likely represent a strong opportunity in the market.





CLRB Announces News With Regard To PDC Molecules

As mentioned above, Cellectar Biosciences had a strong day in the market yesterday after announcing that it has generated numerous PDC molecules that show significant improved pharmacologic activity when compared to payload molecules alone.




The new compounds that CLRB has formulated are specifically designed for improved tumor targeting and fewer off-target adverse effects. According to the PR the company releaseed yesterday, the phospholipid ether molecules provide a greater than 20-fold increase in delivery of PDC to cancerous cells on average. In a statement, Jim Caruso, President and CEO of Cellectar Biosciences, had the following to offer…

The rapid advancement and positive data from these research programs, coupled with our ongoing collaborations, further validate the unique capabilities and broad utility of our PDC platform… We continue to drive our key internal programs in a strategic and cost-efficient manner including the advancement of candidate molecules from these new compound series. The company anticipates sharing additional technical details of this work either in peer reviewed journal articles or at a future oncology conference.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CLRB. In particular, we’ll be keeping a close eye on their ongoing work surrounding their PDC platform as the more news that comes out, the more exciting the prospects become. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 304
Novavax, Inc. NVAX Stock News

Novavax, Inc. (NASDAQ: NVAX) is having an overwhelmingly strong start to the trading session in the pre-market hours this morning, and for good reason. The company announced preclinical data with regard to a vaccine candidate, leading to excitement among investors and sending the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:05), NVAX is trading at $1.07 per share after a gain of $0.07 per share or 7.00% thus far today.





NVAX Gains On Preclinical Data

As mentioned above, Novavax is having a strong start to the day in the pre-market hours after announcing preclinical data surrounding an influenza vaccine candidate. The data came from a preclinical study and has been published in the journal Vaccine. The goal of the vaccine is to protect older adults from seasonal influenza.




The study the data came from was conducted in ferrets. NVAX said that the study found that NanoFlu induced hemagglutination-inhibition and microneutralizing antibodies against a broad range of influenza subtypes. In the study, NanoFlu was shown to elicit higher HAI and MN antibody responses exceeding those induced by the high-dose vaccine against recent (homologous) A(H3N2) by 7-fold, A(H1N1) by 26-fold, and B strain viruses by 2-fold. In a statement, Stanley C. Erck, President and CEO at NVAX, had the following to offer with regard to the data…

Novavax has over a decade of experience in developing both seasonal and pandemic influenza vaccine candidates. Based on the superior attributes of our nanoparticle based vaccine candidates, we transitioned our influenza development activities to our nanoparticle vaccine platform… The data in this publication further validate our nanoparticle vaccine platform and provide a strong rationale for advancing NanoFlu into a Phase 1/2 clinical trial. Our goal is to deliver a superior, differentiated vaccine to the greater than $3 billion global seasonal influenza commercial market.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the company’s ongoing work, not only with regard to NanoFlu, but other vaccines across their robust pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 439
Paratek Pharmaceuticals Inc PRTK Stock News

Paratek Pharmaceuticals Inc (NASDAQ: PRTK) is having an incredibly strong start to the day in the pre-market hours this morning, and for good reason. The company announced that it is considering the sale of the company. Of course, this is leading to excitement among investors who are sending the stock toward the top. As is normally the case, our friends at Trade Ideas were the first to alert us to the gains. At the moment (8:47), PRTK is trading at $24.05 per share after a gain of $5.00 per share (26.25%) thus far today.





PRTK Gains On Sale Exploration

As mentioned above Paratek Pharmaceuticals is having an incredibly strong time in the pre-market hours this morning after the company said that it’s considering putting itself on the auction block. In a report first published on Bloomberg, investors learned that there’s quite a bit of takeover interest surrounding the company as it gets closer and closer to regulatory approval for a new antibiotic. As a result of the strong takeover interest, the company is considering putting itself up for sale.




This news comes just weeks after the company announced that the third study surrounding oral omadacycline proved to be yet another positive one. The treatment performed well against linezolid. With physicians looking for new ways to fight the war against drug-resistant, community-acquired infections, this new drug could be a great option, and an overwhelmingly profitable one at that.

While PRTK will be combing the market to see just how much interest there actually is in a takeover of the company, it’s important to keep in mind that this is a sale exploration at the moment, not a sale. As we learned from Tesaro’s recent exploration, a sale may not happen. Nonetheless, this could be a big acquisition if all goes well.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on PRTK. In particular, we’re interested in following the company’s exploration to see if a sale is the best option for the company and its shareholders. We’re also interested in following the efforts the company is making to bring omadacycline to market. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 271
Intra-Cellular Therapies Inc ITCI Stock News

Intra-Cellular Therapies Inc (NASDAQ: ITCI) is having an incredibly strong start to the trading session today, and for good reason. The company announced news with regard to the FDA, causing excitement among investors who are sending the stock toward the sky. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:22), ITCI is trading at $11.27 per share after a gain of $0.34 per share or 3.11% thus far today.





ITCI Gains On FDA News

As mentioned above, Intra-Cellular Therapies is having a strong day in the market today after announcing some key FDA news. The company said that the United States Food and Drug Administration has informed them that it has completed the review of the company’s responses to requests from the FDA for additional information. The requests surround certain findings observed in nonclinical toxicology studies of lumateperone in animal species. The FDA said that it agrees that ITCI has provided adequate data to support its position that the metabolic pathway in animal species is distinctive from humans, which indicates that toxicity observed in these animals is not relevant to humans.




This is overwhelmingly positive news. After all, after proving to the FDA that the toxicity does not apply to humans, the company is now able to move forward with its long-term safety study surrounding lumateperone. ITCI says that it intends to submit a new drug application for the indication of schizophrenia in mid-2018. In a statement, Dr. Sharon Mates, Chairman and CEI at Intra-Cellular Therapies, had the following to offer…

We are very pleased with the outcome of our discussions with the FDA and look forward to progressing our schizophrenia program.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ITCI. In particular, we’re interested in following the company’s ongoing work surrounding lumateperone and are excited to see the results of these efforts. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









NuLife Sciences NULF Stock News

Technology is the bastion of change. And, at the pace of better science, not only potential but actual changes to lifesaving services and procedures will soon become a reality. For patients in need of organ transplantation, for instance, an emerging company is working to bring to reality the opportunity to reduce many years of waiting time and decrease the exposure to a degraded quality of life standard, as needy patients wait impatiently for either a tissue or organ match compatible for transplantation.

NuLife Sciences believes that they are in a position to reign in the future and is on the cusp of inventing transformational change. While just a micro-cap stock, NULF may become one of the few biomedical companies to advance recellularized human organ transplant technology, and promote medical research that may eliminate the need to locate pre-determined and compatible organ or tissue donors. NULF even goes a step further by potentially eliminating the need for anti-rejection drugs. To those in the industry, they know that if NuLife can accomplish this leap in science that it can transform an industry, allowing organ recipients to eliminate long waiting periods for a matched organ, and can even reduce or eliminate the need for dialysis for patients that are waiting for an acceptable match. Beyond those two extraordinary measures, NuLife Sciences believes that they can also offer the technology to eliminate the need for anti-rejection drugs and to save patients substantial amounts of money just through the reduced cost of medication and the potential elimination of expensive therapies that only treat a disease, but has no curative value.

Put together, what NULF is dedicating its mission toward accomplishing can act as the next transformational step in organ transplantation, and if successful can help the over 123,000 candidates that are currently waiting for a compatible and life-saving organ in the United States alone.

NULF Deserves Better

Despite the fact that the share price is sitting at less than a dollar a share and the trading volume is a bit anemic, the progress made on the clinical front makes NULF a strong candidate for those investors looking for long-term, aggressive, high-risk/high-reward stock to add to their portfolio. As is the case for many emerging biotechs, NULF became part of a technical acquisition by an active, in good standing, publicly traded company. The strategy allowed NULF to immediately take advantages of the benefits of being a public company without the exorbitant costs and time associated with an initial listing application.

From a strategic standpoint, NULF is targeting the treatment of not only the approximate 31,000 organ transplant cases per year but also looking to mark and treat the remaining 120,000 plus patients that are waiting in line. And, the market is not shrinking. Instead, the market is growing, plagued by logistical problems which lead to the death of about 22 people each day, who die in wait for a compatible organ. Imagine, if NULF can generate the science and practices necessary to allow for expedited organ transplantation and eliminate the need for excessive screening, hundreds of lives will get saved each year. But, beyond those hundreds saved, thousands more can be served, not only making organ transplantation compatible to their body but can help to save the medical industry millions of dollars a year in drug cost savings, a portion of which Medicare only covers for three years.

Beyond the dollars saved though, which is a crude comparison when discussing human life, NULF brings much more to the table, benefits that may have a far-reaching effect on an entire industry. Thus, the story becomes ironic in that a small but emerging, sub-dollar stock may hold the key to altering the path of organ science and transplantation procedure. And, despite that the company is still a relatively unknown disruptor of science in a broad landscape of multi-billion dollar companies, NULF may be the one to cause a systemic shift in the industry.

How Will NuLife Pull It Off?

Initially, NULF is looking to target the kidney transplantation market, which since 2015 has averaged roughly 18,500 cases per year. Of all transplants performed, kidney procedures account for the bulk of the action, representing approximately 58% of all cases, followed by liver, heart, lung, and pancreas transplants. Unfortunately, most patients die while waiting for an organ, despite tens of thousands of dollars spent on dialysis, drugs, and treatment. Further complicating the landscape is that all current transplant patients require anti-rejection drugs, the most severe of medications that have been known to cause grave and adverse reactions in patients. But, at this point, or until NULF can produce otherwise, patients will remain mired in the specific drugs despite the debilitating effects. In some cases, notwithstanding the wait for an organ, the anti-rejection drugs prove incapable of doing their job, adding insult to an already dismal situation.

Although NULF only became its own publicly trading company about eight months ago, the science developed through 15 years of committed research, with resulting breakthroughs in both hematopoietic research and transplant techniques. Its goal of the study was to first address the issues of organ compatibility and the need for anti-rejection drugs in both the patient and the donor. During the studies, NULF conducted pilot studies, with its first animal surgery three years ago and an additional three animal patient surgeries in total since 2014.

The technique makes the difference and what NULF is trying to prove is the key to the progress. Like all transplants, the process begins with a healthy donor. From there, the organ goes through a decellularization process to isolate the extracellular matrix of tissue from its inhibiting cells, which is expected to provide an ECM scaffold of the original body tissue. Next, NULF initiates the cell culture process, where specific cells get harvested from the bone marrow of the intended recipient. But, the next step is where the process changes, and if NULF can substantiate its novel and patented technique to the recellularizing process, the method may become a mainstream practice for all transplant cases going forward.

The patented NULF recellularizing process takes particular hematopoietic cells that are used in the process and adds proprietary temperature and pressure factors. Through the associated vacuum process, specific cells get released from platelets without complete platelet degranulation. Coupled with those first two steps, the negative pressure created by the vacuum pulls the growth factors out of the platelets and puts it directly into the plasma. Then, once processed, the cells get reintroduced into the recipient with the intent of influencing the further growth of an already implanted and recellularized organ. Results from the animal studies have been extremely encouraging, and the swine kidneys used in the trial should provide reliable data, as they most closely resemble the kidney to that of humans. Thus, in the recently announced initiation of their pre-clinical study, NULF hopes to demonstrate that after the novel decellularization program, the creation of a kidney scaffold was produced upon which a new organ, unique to the recipient may get successfully rebuilt.

Organ Generation Is No Longer Science Fiction

Ten years ago, the thought of generating or growing an organ suitable for human use was taken seriously by a small handful of scientists. Now, just a decade later, scientists believe that they will soon have the capability to produce certain human organs with the use of 3D printers. While NULF is not prepared to use the 3D method just yet, they are in a way generating results that should demand significant industry attention.

What NULF is demonstrating is that in its animal (swine) studies, it can take a created kidney scaffold and populate it by injection from immature bone marrow cells from the recipient, and then allow the stem cells to differentiate into mature kidney cells. From that point, the growth of the kidney is genetically identical to that of the recipient, which is then provided processed blood to aid the recellularization process before and after the organ is implanted. Now, assuming that NULF continues to generate positive results, not only do potential partnership opportunities arise to expedite the company’s program, but the direct impact that a successful trial can bring to the transplant industry can be enormous.

First things first, let’s highlight the most beneficial aspect of a successful NULF procedure: it can change to days, from years, the time required for a patient to be identified and readied for transplant. This time decrease is in stark difference to the up to 15 years of waiting time seen in many transplant cases. NULF can help eliminate a substantial portion of the “attempt to match” diagnostic testings required before a procedure is performed, and can alter the entire logistical landscape of the industry by being able to work on local opportunities instead of care flight delivered organs, many of which prove to be non-compatible with the recipient. Beyond the logistical and life-saving measure, the direct cost-benefit and savings can be substantial, eliminating the over $17,000 per year required for anti-rejection medication and the upwards of $85,000 per year for dialysis treatment while a patient is waiting for a new kidney.

Yes, money and savings are significant, but it pales to the quality of life benefit that the NULF procedure can afford to patients, increasing mortality rates and at the same time allowing patients to stop taking the debilitating anti-rejection drugs required to remain healthy.

Is NULF close to approval? Well, investors should not assume that the company will be commercializing the procedure within the next year. However, NULF has identified a pathway to commercialization which offers an insight as to the progress made by the company. As stated earlier, the progress made is a culmination of over 15 years of dedicated science and research, which was initially used as a process to heal wounds. From the technology end, the discovery process was born, and patent applications were filed and granted in 2015 which provides critical protection over proprietary processes and intellectual property, enabling the company to enter into potential partnership agreements more securely.

From NULF discovery came the first preclinical experiments. During a three-month period, with one procedure per month on three different animals, the company produced approximately 12 different tests, each with a specialized focus on specific research and planned study outcomes. The current animal studies are being performed in collaborations with both Florida International University and Nova Southeastern University, with the aim of encouraging opinion that additional animal studies should be conducted to determine the direction of the program. The pre-clinical animal studies are expected to continue throughout 2017, with results announced soon after completion, also planned for late 2017. Once complete, NULF plans to complete appropriate documentation protocol, expand its advisory board, and to meet with the FDA to propose a clinical pathway to commercialization, also expected to process in the second half of 2017.

It’s Not All About Transplants, Though

Although the primary target of NULF technology is to expedite organ transplantation, the technology has other far-reaching applications. With two patents granted that protect significant aspects of organ transplant procedure, the company has a 17-year window of protection that begins at the conclusion of its clinical investigator’s program. In addition to the patent protection, NULF expects to file with the FDA an application to become fully licensed for the comprehensive use of cytokines and be granted a 14-year window of exclusivity for process and therapy.

Getting the help from both the patent board and the FDA will contribute to expediting clinical programs as well as to protect intellectual property. From where NULF currently sits, they can advance research for transplantation factors of other vital organs.

In addition to the role in transplant, NULF believes that they are well-placed to expand the technology into additional fields that can work to assist in the building of the immune system. Further research demonstrated the potential to improve chronic wound closures, offer preventive care and to bring to the market novel and innovative methods for treating an array of patient conditions having to do with cellular or wound technology.

Managed by a respectable team of medical professionals and advisers, NULF had slightly over 31 million shares outstanding as of May 2017. Like most emerging and potentially transformative companies, NULF will likely need to raise additional funds to shore up the cost of future studies. While other collaborations or partnerships may reduce the company’s operating cost, NULF is getting to the point whereby raising cash on their own and not giving away excessive equity may indeed be a better long-term road to follow. For those with a long-term horizon and are more than willing to let this emerging company continue to prove its science, getting into the stock at these prices may be an exceptional long-term proposition. At less than a dollar per share, if the company does raise money, it will be dilutive, so taking a cost average approach into NULF may be advisable.

One thing is for certain, if NULF is successful in developing this revolutionary approach to transplantation, patients and investors will benefit. That, in and of itself, is an investable thesis and the value proposition in the technology already is worthy of a share price in excess of current market value.

Disclaimer- CNA Finance is NOT an Investment Advisor. Our goal is to bring both news and under discovered stocks to the attention of investors to assist in making smart decisions in the market. CNA Finance is a for profit company. That profit is generated through three (3) different types of relationships. First and foremost, we work with pay per click and CPM advertisers on banners. We also have affiliate relationships with various companies where we earn a portion of the sales we refer. Finally, we may have relationships with some of the companies or IR firms that represent companies mentioned within our works in which we are compensated in cash and or stock for consulting, investor relations, and Press Release services. Worldwide Holdings paid CNA Finance $3,000 to hire Perceptive Analytics for research and writing services as well as other investor relations services provided to NuLife Sciences by CNA Finance. All information researched and provided through any article associated with NuLife Sciences and published on CNA Finance is public information that is documented and available upon request. CNA Finance encourages all investors to seek professional advice before making any investment decision.

0 2974
Delcath Systems, Inc. DCTH Stock News

Delcath Systems, Inc. (NASDAQ: DCTH) is having a relatively rough start in the pre-market hours this morning after receiving notice of delisting from NASDAQ. Unfortunately, this seems to be causing fear among investors, sending the stock toward the bottom. However, there is a light at the end of the tunnel here folks, and I intend to show it to you. Before I do, I’d like to give a quick thanks to our friends at Trade Ideas for being the first to alert us to the movement. At the moment (7:54), DCTH is trading at $0.12 per share after a loss of $0.02 per share (12.25%) thus far today.





DCTH Informs Investors Of Potential NASDAQ Delisting

As mentioned above, Delcath Systems is having a rough day today, as investors seem to be finding an 8K that was filed by the company yesterday. In the 8K, the company informed investors that it has received written notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC. The notice indicated that, based on non-compliance with the minimum stockholder’s equity requirement for continued listing on the NASDAQ Capital Market, the company will be delisted from the index. That is, unless DCTH provides a timely request for a hearing before the NASDAQ Hearings Panel.




In the 8K, DCTH said that they do indeed intend to request a hearing, which has the potential to stay any delisting action until the hearing concludes and any extension provided by the Hearing Panel expires. During the hearing, Delcath Systems intends to present a plan to bring the stock back to compliance as well as request an extension of time in which the company has to do so.

The Light At The End Of The Tunnel

As mentioned above, while the concept of delisting is indeed scary for many, there is a light at the end of the tunnel here. Well, the truth is that there are a couple of lights:

  • Extension – Considering that DCTH is actively requesting a hearing and has put together a plan in order to bring the stock into compliance, chances are that the company will indeed receive an extension from the NASDAQ. As a result, they’ll have a bit more time to get that stock price up to that magic $1-per-share mark.
  • Results – As mentioned in yesterday’s post surrounding the company, DCTH is currently working on a clinical study that is set to end in September of this year. Well my friends, September is only 9 days away. Can someone say “Catalyst?”
  • Life Saving Technology – Finally, do yourself a favor and search YouTube for either Delcath Systems or Chemosat. Now, take a few minutes to watch videos of patients who had no other option, but decided to move forward with Chemosat. Yes, many of them are still here today, making videos as a thank you to DCTH for the life saving technology they have made available to these patients. If that’s not a reason to be excited about this company, I don’t know what is!

Chemosat Is A Great Treatment Option

If you’re concerned that Chemosat won’t be used much in the United States once it’s approved, allow me to alleviate your concerns. So far, the treatment has been approved in the UK and Europe, and it is being used quite regularly. In fact, there was a press conference on Chemosat from a German hospital on Friday. The conference was an exciting one in which hospital staff discussed data after completing 100 Chemosat treatments and saving lives in the process. They are the second hospital that has completed treatment of 100 patients using this relatively new, yet life saving technology, and I’m sure there will be plenty more coming down the line!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on DCTH. In particular, we’re interested in following the listing news, the clinical data that’s likely coming in September, and the ongoing life-saving efforts made by the company and doctors in Europe and the UK that are taking advantage of this incredible technology. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 363
Tenet Healthcare Corp THC Stock News

Tenet Healthcare Corp (NYSE: THC) is having an incredible time in the market today, posting strong gains for the second trading session in a row. Ultimately, the gains are the result of management changes that were announced late last week, causing excitement among investors. As is normally the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (11:33), THC is trading at $16.93 per share after a gain of $2.48 per share or 17.16% thus far today.





THC Gains On Management Changes

As mentioned above, Tenet Healthcare is having an incredibly strong trading session today, following up on the gains we saw from the stock on Friday. At the end of the day, the gains are all associated with recent news of management changes that broke late on Thursday.

Late Thursday, THC announced that both Randy Simpson and Matt Ripperger had provided their resignation and that these resignations were effective immediately. The two were both members of the company’s Board of Directors and represented the interests of Glenview Capital Management, an asset management firm that holds a substantial stake in THC. Ultimately, the resignation was the result of what the two Board members said were irreconcilable differences in the way the overall Board has approached various strategic issues.




So, where are the gains coming from? Well, with the resignation of these two key Board members, investors are expecting a bit of a fight. In fact, many are saying that a full-blown proxy fight between Glenview Capital Management and Tenet Healthcare will be coming down the line relatively soon. While this may not sound so positive, this type of fight could lead to incredible shareholder-friendly concessions.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on THC. In particular, we’re interested in following the war that may be waged between THC and Glenview and the result of this battle. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 539
FalconStor Software, Inc. FALC Stock News

FalconStor Software, Inc. (NASDAQ: FALC) is breaking the law – well, the law of gravity that is. The company announced key management changes last week that excited investors, sending the stock on a run of around 77% growth. However, as we enter this week, that run is far from ending. In fact, early this morning, we received another alert from our friends at Trade Ideas, informing us that the stock seems to have grown yet another pair of wings. At the moment (10:30), FALC is trading at $0.37 per share after a gain of $0.13 per share (51.13%) thus far today.





FALC Gains On Leadership Changes

As mentioned above, FalconStor Software is having yet another incredible day in the market today, following up on last week’s gains. The gains are ultimately the result of key management changes that were announced late last week. In particular, the company appointed Todd Brooks as the CEO and Patrick McClain as the CFO. Both appointments were announced as effective immediately. In a statement, Todd Brooks, the new CEO at FALC, had the following to offer:




FalconStor’s long-term position as a leader in data storage management software and extensive enterprise customer base are tremendous assets for the Company… to maximize these assets, the Company’s commercial and operational fundamentals must be refocused. I am excited to lead these efforts and position FalconStor for long-term success delivering differentiated value to our customers and shareholders.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on FALC. In particular, we’re interested in following the changes made by the new leadership and excited to see the results of these changes. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required









0 315
Tonix Pharmaceuticals Holding Corp TNXP Stock News

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is having a pretty strong start to the trading session this morning, and for good reason. The company announced that it will be providing various poster presentations with regard to clinical data surrounding Tonmya*, also known as TNX-102 SL. Of course, this caused excitement among investors, sending the stock toward the sky. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:31), TNXP is trading at $3.12 per share after a gain of $0.17 per share or 5.76% thus far today.





TNXP Gains On Clinical Update

As mentioned above, Tonix Pharmaceuticals is having a relatively strong start in today’s trading session after providing investors with news of a coming clinical update. The company said that it would be providing poster presentations at the 2017 Military Health System Research Symposium, which will be held August 27th through August 30th in Kissimmee Florida. Chief Medical Officer of TNXP, Gregory M. Sullivan, M.D., will be the presenter of the following poster presentations…




  • Poster #521: Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response (Abstract ID: MHSRS-17-1685).
  • Poster #519: Efficacy of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301) (Abstract ID: MHSRS-17-1626).

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on TNXP. In particular, we’re interested in following the ongoing work surrounding TNX-102 SL as the treatment has shown some promising results in previous studies. Not to mention, the breakthrough therapy designation makes it an even more promising prospect. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 5281
Delcath Systems Inc DCTH Stock News

Delcath Systems, Inc. (NASDAQ: DCTH) has been an incredibly interesting stock to watch as of late. We’ve seen ups, we’ve seen downs, and we’ve seen the debates. Nonetheless, there are several very good reasons to hang on here, and one of them is that September could be an incredibly strong month. Before we get into why, we’d like to give a big thank you to our friends at Trade Ideas for keeping the stock on our radar. At the moment (8:12), DCTH is trading at $0.16 per share after a gain of $0.01 per share (5.41%) thus far today.





Why September Could Be A Very Big Month For DCTH

As mentioned above, Delcath Systems has seen its ups and downs recently, but some big and overwhelmingly positive movement could be coming down the line – and very soon. That’s because a key clinical trial is scheduled to be completed just next month.




In a document found on ClinicalTrials.gov, there are published dates surrounding a study titled “Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients with Unresectable HCC”. While the study was first submitted on March 23, 2015, it should be coming to an end relatively soon. In fact, the documentation linked to above says that DCTH expects final data collection for the primary outcome measure to happen this month. On top of that, study completion is expected in September.

Considering previous data surrounding Chemosat by DCTH, it only makes sense that data from this trial is likely to be positive. While the company continues to save lives in Europe, an approval in the United States would be a massive win for Delcath Systems, and the data release that should be coming soon will bring the company one step closer to that goal.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on DCTH. In particular, we’re interested in following the company’s ongoing work to bring Chemosat to patients in need in the United States. Also, we haven’t seen an official release from the company with regard to the potential stock split. While there are some reports suggesting that investors voted against it, we’re awaiting official word from the company. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 6241
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...